Novartis launches rivastigmine patches for mild to moderately severe Alzheimer’s dementia .

Title Novartis launches rivastigmine patches for mild to moderately severe Alzheimer’s dementia
Date Published 22/10/2007
Reporter initials Hina
Reporter surname Radia
Reporter affiliation Hospital Pharmacist
Source Personal communication, Novartis Pharmaceuticals, 19 October 2007
Abstract Novartis Pharmaceuticals has announced the launch of rivastigmine (Exelon) patches licensed for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia.

The following patch strengths are available:
• Exelon 4.6 mg/24 h; 30 patches – basic NHS cost = £83.84
• Exelon 9.5 mg/24 h; 30 patches – basic NHS cost = £83.84

Dehydrodidemnin B ( Aplidin , Plitidepsin ) Patente US .

Dehydrodidemnin B

Publication number: USRE39887E
Publication date: 2007-10-16
Inventor: RINEHART KENNETH L (US); LITHGOW-BERTELLONI ANNA M (ES)
Applicant: PHARMA MAR SA (ES)
Classification:
- international: C07K7/00; C07K7/00;
- European:
Application number: US20050145507 20050602
Priority number(s): GB19890022026 19890929; US19940280110 19940725; WO1990GB01495 19901001; US20050145507 20050602


Abstract of USRE39887E

Dehydrodidemnin B with useful biological activity has formula (1). It can be isolated from natural sources or synthesized, and it forms active derivativ

Yondelis , Recomendaciones e Indicaciones segun la EMEA .

El cáncer de próstata también afecta a las esposas de los pacientes que lo padecen .

Eficacia de lapatinib en pacientes HER2 que han fracasado con trastuzumab .

Nueva clasificación de los tumores gracias a tratamientos biológicos .

Mastectomía profiláctica, recurso excepcional en cáncer de mama .

Oncologia , La terapia hipofraccionada reduce las sesiones .